CRISM Therapeutics Corporation (CRTX) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.775x

Based on the latest financial reports, CRISM Therapeutics Corporation (CRTX) has a cash flow conversion efficiency ratio of -0.775x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.10 Million ≈ $-133.59 USD) by net assets (GBX1.42 Million ≈ $172.29 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRISM Therapeutics Corporation stock valuation for the company's overall valuation and market capitalisation.

CRISM Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how CRISM Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CRISM Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CRISM Therapeutics Corporation ranked by their cash flow conversion efficiency. Explore CRTX cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
PowerHouse Energy Group Plc LSE:PHE	-0.190x
Tern Plc LSE:TERN	-0.090x
BSR Real Estate Investment Trust TO:HOM-UN	-0.022x
Bay Capital PLC LSE:BAY	-0.315x
Hydrogenone Capital Growth PLC LSE:HGEN	-0.012x
Cloudbreak Discovery PLC LSE:CDL	1.916x
NB Distressed Debt New Glb LSE:NBDG	-0.006x
Catalyst Media Group PLC LSE:CMX	-0.002x

Annual Cash Flow Conversion Efficiency for CRISM Therapeutics Corporation (2006–2025)

The table below shows the annual cash flow conversion efficiency of CRISM Therapeutics Corporation from 2006 to 2025. View CRTX stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	GBX1.42 Million ≈ $172.29	GBX-1.97 Million ≈ $-239.33	-1.389x	-119.61%
2024-12-31	GBX1.48 Million ≈ $179.46	GBX-933.00K ≈ $-113.52	-0.633x	-117.35%
2023-12-31	GBX-759.66K ≈ $-92.43	GBX-2.77 Million ≈ $-337.03	3.646x	+2499.16%
2022-12-31	GBX23.13 Million ≈ $2.81K	GBX-3.52 Million ≈ $-427.67	-0.152x	-149.67%
2021-12-31	GBX30.11 Million ≈ $3.66K	GBX-1.83 Million ≈ $-223.02	-0.061x	+16.44%
2020-12-31	GBX31.35 Million ≈ $3.81K	GBX-2.28 Million ≈ $-277.87	-0.073x	+21.54%
2019-12-31	GBX20.48 Million ≈ $2.49K	GBX-1.90 Million ≈ $-231.42	-0.093x	+11.24%
2018-12-31	GBX23.48 Million ≈ $2.86K	GBX-2.46 Million ≈ $-298.79	-0.105x	-9.13%
2017-12-31	GBX28.20 Million ≈ $3.43K	GBX-2.70 Million ≈ $-328.88	-0.096x	-22.05%
2016-12-31	GBX25.55 Million ≈ $3.11K	GBX-2.01 Million ≈ $-244.14	-0.079x	+60.09%
2015-12-31	GBX15.21 Million ≈ $1.85K	GBX-2.99 Million ≈ $-364.05	-0.197x	-108.05%
2014-12-31	GBX20.72 Million ≈ $2.52K	GBX-1.96 Million ≈ $-238.43	-0.095x	-5.53%
2013-12-31	GBX18.05 Million ≈ $2.20K	GBX-1.62 Million ≈ $-196.88	-0.090x	-92.36%
2012-12-31	GBX16.12 Million ≈ $1.96K	GBX-750.98K ≈ $-91.37	-0.047x	+63.01%
2011-12-31	GBX21.19 Million ≈ $2.58K	GBX-2.67 Million ≈ $-324.75	-0.126x	-244.69%
2010-12-31	GBX21.29 Million ≈ $2.59K	GBX-778.08K ≈ $-94.67	-0.037x	+28.46%
2009-12-31	GBX16.52 Million ≈ $2.01K	GBX-843.95K ≈ $-102.68	-0.051x	+73.28%
2008-12-31	GBX10.78 Million ≈ $1.31K	GBX-2.06 Million ≈ $-250.79	-0.191x	-80.39%
2007-12-31	GBX6.53 Million ≈ $795.02	GBX-692.47K ≈ $-84.25	-0.106x	+0.92%
2006-12-31	GBX9.33 Million ≈ $1.14K	GBX-998.08K ≈ $-121.44	-0.107x	--

About CRISM Therapeutics Corporation

LSE:CRTX UK Biotechnology

Market Cap

$108.39K

GBX890.83 Million GBX

Market Cap Rank

#31480 Global

#1114 in UK

Share Price

GBX11.25

Change (1 day)

+0.00%

52-Week Range

GBX8.75 - GBX17.50

All Time High

GBX2425.08